Zentalis Pharmaceuticals announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for presentation at the 2026 ASCO Annual Meeting in Chicago, scheduled for June 1‑5, 2026. The abstract, titled “Azenosertib Plus Paclitaxel for Platinum‑Resistant Ovarian Cancer: Results From a Phase 1b Study,” will be presented in a poster session on June 1.
The acceptance is based on data from Part 1 of the MUIR trial, which evaluated azenosertib—a WEE1 inhibitor—in combination with paclitaxel in patients with platinum‑resistant ovarian cancer. The data demonstrate safety, tolerability, and preliminary clinical activity, suggesting that azenosertib may have broader applicability beyond its biomarker‑selected monotherapy program.
Zentalis CEO Julie Eastland said the abstract acceptance confirms the company’s strategy to explore azenosertib in both biomarker‑selected and all‑comer settings. She noted that paclitaxel is a widely used chemotherapy agent and that the combination data highlight azenosertib’s potential to enhance treatment efficacy in platinum‑resistant ovarian cancer.
The company’s focus on Cyclin E1‑positive PROC is supported by Fast Track designation from the FDA and ongoing registration‑intended trials (DENALI and ASPENOVA). The MUIR data presentation at ASCO provides an early opportunity to showcase combination therapy results to the oncology community and may inform future clinical development strategies.
Zentalis remains a clinical‑stage biotech with no approved products and a cash balance of $245.9 million as of December 31 2025, projected to fund operations into late 2027. The abstract acceptance is a key milestone that could strengthen investor confidence in the company’s pipeline and support future fundraising or partnership opportunities.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.